Allergan Moves in as Shire Rebuffs $63 billion Takeda Bid
Drugmaker Shire has rejected a third takeover bid worth nearly $63 billion from Japan’s Takeda Pharmaceutical, although talks are continuing, while sources said Allergan was also in competing negotiations, according to Reuters.
It is not clear whether Botox maker Allergan has submitted an offer, and there is no certainty of a bid from the U.S. group, people familiar with the matter said on Thursday.
Reuters first reported that Takeda had made a cash-and-stock takeover offer of 46.50 pounds ($66.20) a share, prompting Takeda to issue a statement confirming the move.
